Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Moderna Slipped Lower Today

By Brian Orelli, PhD - Feb 12, 2020 at 12:12PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A secondary offering causes dilution for the biotech.

What happened

Shares of Moderna (MRNA 0.70%) are down 11% at 12:39 p.m. EST after the company priced its secondary offering at $19 per share, allowing the biotech to raise approximately $500 million. The company could get an additional $75 million or so if the underwriters exercise the 30-day option to purchase additional shares.

So what

Shares of Moderna closed at $21.35 yesterday, so it's not surprising that they would take a hit today. Buyers of secondary offerings typically seek a discount to the current price because selling the additional shares results in dilution.

With shares well off their lows of last year, it's a fairly good time for the biotech to raise additional capital, considering the company's pipeline is only in the very early stages of the drug-development marathon. Management was shooting for having $1.2 billion in the bank at the end of last year -- it hasn't released fourth-quarter financials yet -- but that won't be enough to get it to the finish line since its burn rate is likely to increase as the pipeline progresses.

Magnifying glass and pen on a balance sheet

Image source: Getty Images.

Earlier this week, Moderna moved its seventh drug into the clinic, starting a clinical trial for mRNA-3704 in patients with a rare genetic disease called isolated methylmalonic acidemia, which is typically caused by a mutation in a gene called mitochondrial enzyme methylmalonic-CoA mutase (MUT). Like Moderna's other drugs, mRNA-3704 is an mRNA that allows the cells to express a needed protein -- in this case MUT.

Now what

Dilution is never fun for investors since it results in each share representing a smaller piece of the pie. But the additional capital should help Moderna grow the size of the pie, ultimately rewarding investors for their patience.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$144.27 (0.70%) $1.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.